Why is Beryl Drugs falling/rising?

As of 12-Sep, Beryl Drugs Ltd is experiencing a price increase, currently at 24.30, which reflects a rise of 0.5 or 2.1%. The stock has outperformed its sector today by 1.81%. However, despite this positive movement, there are concerns regarding falling investor participation, as the delivery volume on 11 September decreased by 52.81% compared to the 5-day average. The stock's performance over the past week shows a modest gain of 1.21%, while it has significantly outperformed the benchmark Sensex over the past month with a return of 32.07% compared to the Sensex's 2.08%. The stock is currently trading above its 20-day, 50-day, and 100-day moving averages, but below its 5-day and 200-day moving averages, indicating mixed signals regarding its momentum.
In the broader market context, Beryl Drugs' recent performance contrasts with the benchmark Sensex, which has shown a return of 1.48% over the past week. While the stock has had a strong month, its year-to-date performance remains negative at -32.78%, compared to the Sensex's positive return of 4.82%. This suggests that while the stock is currently rising, it has struggled significantly over a longer timeframe, which may be affecting investor sentiment. Overall, the combination of recent price gains and declining participation could indicate a cautious outlook among investors, despite the stock's short-term outperformance.